User profiles for "author:Eric A Cohen"

Eric A Cohen

- Verified email at sunnybrook.ca - Cited by 20571

Éric A. Cohen

- Verified email at ircm.qc.ca - Cited by 14347

Myonecrosis after revascularization procedures

RM Califf, AE Abdelmeguid, RE Kuntz… - Journal of the American …, 1998 - jacc.org
The detection of elevated cardiac enzyme levels and the occurrence of electrocardiographic
(ECG) abnormalities after revascularization procedures have been the subject of recent …

International AIDS Society global scientific strategy: towards an HIV cure 2016

SG Deeks, SR Lewin, AL Ross, J Ananworanich… - Nature medicine, 2016 - nature.com
Antiretroviral therapy is not curative. Given the challenges in providing lifelong therapy to a
global population of more than 35 million people living with HIV, there is intense interest in …

[HTML][HTML] Modulation of HIV-1-host interaction: role of the Vpu accessory protein

M Dubé, MG Bego, C Paquay, ÉA Cohen - Retrovirology, 2010 - Springer
Viral protein U (Vpu) is a type 1 membrane-associated accessory protein that is unique to
human immunodeficiency virus type 1 (HIV-1) and a subset of related simian …

[HTML][HTML] Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events

DL Bhatt, KAA Fox, W Hacke, PB Berger… - … England Journal of …, 2006 - Mass Medical Soc
Background Dual antiplatelet therapy with clopidogrel plus low-dose aspirin has not been
studied in a broad population of patients at high risk for atherothrombotic events. Methods …

Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention …

AM Lincoff, JA Bittl, RA Harrington, F Feit, NS Kleiman… - Jama, 2003 - jamanetwork.com
ContextThe direct thrombin inhibitor bivalirudin has been associated with better efficacy and
less bleeding than heparin during coronary balloon angioplasty but has not been widely …

Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial

DL Bhatt, MD Flather, W Hacke, PB Berger… - Journal of the American …, 2007 - jacc.org
Objectives: The purpose of this study was to determine the possible benefit of dual
antiplatelet therapy in patients with prior myocardial infarction (MI), ischemic stroke, or …

[HTML][HTML] Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary …

EJ Topol, DJ Moliterno, HC Herrmann… - … England Journal of …, 2001 - Mass Medical Soc
Background In the setting of percutaneous coronary revascularization, agents in the class
known as platelet glycoprotein IIb/IIIa inhibitors have significantly reduced the incidence of …

[HTML][HTML] Routine early angioplasty after fibrinolysis for acute myocardial infarction

WJ Cantor, D Fitchett, B Borgundvaag… - … England Journal of …, 2009 - Mass Medical Soc
Background Patients with a myocardial infarction with ST-segment elevation who present to
hospitals that do not have the capability of performing percutaneous coronary intervention …

The Canadian study of the sirolimus-eluting stent in the treatment of patients with long de novo lesions in small native coronary arteries (C-SIRIUS)

E Schampaert, EA Cohen, M Schlüter, F Reeves… - Journal of the American …, 2004 - jacc.org
Objectives: We assessed the safety and effectiveness of the sirolimus-eluting stent (SES) in
treating single de novo long lesions in small native coronary arteries compared to an …

Long-term efficacy of bivalirudin and provisional glycoprotein IIb/IIIa blockade vs heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary …

AM Lincoff, NS Kleiman, DJ Kereiakes, F Feit, JA Bittl… - Jama, 2004 - jamanetwork.com
ContextIn the Randomized Evaluation in PCI Linking Angiomax to Reduced Clinical Events
(REPLACE)-2 trial, bivalirudin with provisional glycoprotein IIb/IIIa (Gp IIb/IIIa) inhibition was …